Stockholm, 2016-10-31 10:06 CET (GLOBE NEWSWIRE) --
The Chairman of PledPharma AB has established a Nomination Committee for the Annual General Meeting that is to be held on April 25, 2017.
The Nomination Committee consists of Staffan Persson, Peter Lindell and Astrid Samuelsson. The members of the Nomination Committee have been appointed by PledPharma’s three major shareholders. The Nomination Committee has elected Staffan Persson as convener for the Committee. Håkan Åström (Chairman of PledPharma) has been co-opted to the Nomination Committee.
The Committee's task is to present to the Annual General Meeting proposals regarding Chairman and other members of the board as well as fees and other remuneration to the Board´s members. The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals to the process to appoint the Nomination Committee for the AGM in 2018.
Shareholders who wish to submit proposals to the Nomination Committee can do so by email: hakanastrom@aol.com
For more information please contact:
Håkan Åström, Chairman, phone: +46 703 747 213
Jacques Näsström, CEO, phone: +46 737 130 979
jacques.nasstrom@pledpharma.se
About PledPharma
PledPharma develops new drugs that protect the body against oxidative stress – a potentially debilitating and sometimes life-threatening condition that can be caused by chemotherapy treatment and following acetaminophen (paracetamol) overdose. The company's most advanced project PledOx® reduces nerve damage associated with chemotherapy and positive results from the Phase IIb study PLIANT were presented during the spring of 2015. The drug candidate Aladote® is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning.
PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 80 00). For more information, see www.pledpharma.se
